Drug review process in the management of potential polypharmacy
CRITERIA / CONSIDERATIONS | PROCESS/GUIDANCE | References / Further reading or Examples | |
1 | Is there a valid and current indication? Is the dose appropriate? | Identify medicine and check that it does have a valid and current indication in this patient with reference to local formulary. Check the dose is appropriate (over/under dosing?) | e.g. PPIs- use minimum dose to control GI symptoms - risk of c.difficle and fracture e.g. long term antibiotics |
2 | Is the medicine preventing rapid symptomatic deterioration? | Is the medicine important/essential in preventing rapid symptomatic deterioration? If so, it should usually be continued or only be discontinued following specialist advice. | e.g. Medications for Heart failure, medications for Parkinson's Disease are of high day to day benefit and require specialist input if being altered. review of doses may be appropriate e.g. digoxin |
3 | Is the medicine fulfilling an essential replacement function? | If the medicine is serving a vital replacement function, it should continue. | e.g. thyroxine and other hormones |
4 | Consider medication safety Is the medicine causing:
| Contraindicated drug or high risk drugs group? Strongly consider stopping Poorly tolerated in frail patients? Consider stopping Particular side effects? May need to consider stopping | |
5 | Consider drug effectiveness in this group/person? | For medicines not covered by steps 1 to 4 above, compare the medicine to the 'Drug Effectiveness Summary' which aims to estimate effectiveness. | |
6 | Are the form of medicine and the dosing schedule appropriate? Is there a more cost effective alternative with no detriment to patient care? | Is the medicine in a form that the patient can take supplied in the most appropriate way and the least burdensome dosing strategy? Is the patient prepared to take the medication? UKMI Guidance on choosing medicines for patients unable to swallow solid oral dosage forms should be followed. | Consideration should be given to the stability of medications. Ensure changes are communicated to the patients' Pharmacist: Would this patient benefit form Chronic medication Service? |
7 | Do you have the informed agreement of the patient/carer/welfare proxy? | Once all the medicines have been through steps 1 to 6, decide with the patient/carer/or welfare proxies what medicines have an effect of sufficient magnitude to consider continuation/discontinuation. |
For full details then see Polypharmacy Quick Reference Guidance for Clinicians October 2012
Notes:
Reference:
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page